Triple threat vaccine aims to shield seniors from three winter viruses
NCT ID NCT07295028
First seen Jan 06, 2026 · Last updated Jun 02, 2026 · Updated 19 times
Summary
This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and how well it triggers the immune system, comparing it to existing vaccines and a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emeritus Research
Camberwell, Australia
-
Momentum Clinical Research
Darlinghurst, Australia
-
University of Sunshine Coast, South Bank
Brisbane, Australia
-
University of the Sunshine Coast
Morayfield, Australia
-
University of the Sunshine Coast, Sippy Downs
Sippy Downs, Australia
-
Veritus Research
Melbourne, Australia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.